Page 302 - Binder2

• Not just one drug for all, but many crops for many
needs
• Adaptive treatment cycles based on immune
monitoring
• And, someday, patient-specific prescriptions filled
not by compounding pharmacists—but by biotech
farmers

Redesigning the Biologic Lifecycle

Edible biologics don’t just change how drugs are made and
taken—they reframe the lifespan of a therapy. Instead of a
linear path from molecule to market to obsolescence, plant-
based systems allow for iterative, modular, and regenerable
biologics.

A failed batch isn’t a $2 million loss. It’s a few trays of
lettuce.
A new variant doesn’t require a facility overhaul—just a
DNA edit and a planting schedule.
A supply chain disruption doesn’t halt production—it
redirects it.

This turns biologics from brittle assets into resilient
platforms. Therapies can evolve with disease. Production
can adapt to demand. And biologics—finally—can be
treated not as fixed commodities, but as living systems.

We’ve spent decades building biologics that are powerful,
but inflexible.
Edible biologics flip the paradigm.

300